STD Med, Pavilion announce joint investment to launch Saphena Medical

NewsGuard 100/100 Score

Pavilion Medical Innovations L.L.C. of  Norwell, MA and STD Med, Inc. of Stoughton, MA are pleased to announce a joint investment to launch Saphena Medical, Inc., a new cutting edge medical device company focused on Endoscopic Vein Harvesting technologies. Its OnePass™ platform delivers single-step, minimally-invasive harvesting of veins used for coronary artery bypass grafting. The company recently raised $3 million in Series A funding to take the OnePass™ platform through regulatory clearance.

Saphena Medical, located at the STD Med Innovation Center in West Bridgewater, MA is the fifth start-up technology company for OEM STD Med, Inc. and also the fifth for Pavilion founders, who most recently sold Vortex Medical to AngioDynamics.

Pavilion founder Michael Glennon , who will serve as the President of Saphena Medical says, "This funding and our close working relationship with the experts at STD Med will enable Saphena Medical to rapidly move our game changing platform technology through all the processes required for commercialization".   Andrea Patisteas , Senior Executive VP at STD Med said, "We are excited to join with Pavilion and share resources and expertise to successfully bring Saphena Medical's technology to market." "We both bring a lot to the table," said Steven Tallarida , President of STD Med. "Medical device incubators need to get their products to market faster and more cost effectively and that's how Mike Glennon 's model works."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates